Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Subscribe To Our Newsletter & Stay Updated